Conduct unbecoming: C-reactive protein interactions with a broad range of protein molecules

被引:17
作者
Boguslawski, George
McGlynn, Patrick W.
Potempa, Lawrence A.
Filep, Janos G.
Labarrere, Carlos A.
机构
[1] Methodist Res Inst, Clarian Hlth Partners, Indianapolis, IN 46202 USA
[2] Univ Montreal, Maisonneuve Rosemont Hosp, Res Ctr, Montreal, PQ, Canada
基金
加拿大健康研究院;
关键词
D O I
10.1016/j.healun.2007.04.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: C-reactive protein (CRP), a pentamer composed of five identical 23-kd subunits,. is a member of a highly conserved family of proteins known as pentraxins. CRP has been recognized as a risk factor for the development of both the native and transplant-associated. forms of atherosclerosis. Understanding the biology of CRP may be relevant to understanding atherosclerosis development and progression. Methods: Using Western-blotting techniques, we examined the interactions between native, monomeric and mutationally and chemically modified CRP and a variety of antibodies, monoclonal and polyclonal. Results: CRP in its denatured monomeric form, but not in its native pentameric conformation, associates promiscuously with IgG molecules, including normal human IgG, as well as with a number of other proteins. This behavior is intrinsic to CRP and is not noted with other pentraxins such as serum amyloid P component or the long pentraxin, PTX3. Monomeric CRP co-localizes with vitronectin in human heart tissue sections. Conclusions: We present these findings as cautionary advice, to indicate that characterization of monomeric CRP can be complicated by the propensity of the molecule to interact with a variety of immunoglobulins and other proteins. We also suggest that it is possible that such interactions could serve to eliminate excess of monomeric CRP and/or to scavenge altered, damaged and denatured proteins. These reactivities may be part of a regulatory mechanism to limit inflammation in the arterial wall.
引用
收藏
页码:705 / 713
页数:9
相关论文
共 48 条
[1]   A C-reactive protein mutant that does not bind to phosphocholine and pneumococcal C-polysaccharide [J].
Agrawal, A ;
Simpson, MJ ;
Black, S ;
Carey, MP ;
Samols, D .
JOURNAL OF IMMUNOLOGY, 2002, 169 (06) :3217-3222
[2]   Analysis of binding sites in human C-reactive protein for FcγRI, FcγRIIA, and C1q by site-directed mutagenesis [J].
Bang, R ;
Marnell, L ;
Mold, C ;
Stein, MP ;
Du Clos, KT ;
Chivington-Buck, C ;
Du Clos, TW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (26) :25095-25102
[3]  
Bell SA, 1998, CLIN EXP IMMUNOL, V113, P327
[4]   C-reactive protein [J].
Black, S ;
Kushner, I ;
Samols, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (47) :48487-48490
[5]   C-reactive protein and other inflammatory risk markers in acute coronary syndromes [J].
Blake, GJ ;
Ridker, PM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (04) :37S-42S
[6]  
Boguslawski G, 2006, KARDIOCHIR TORAKOCHI, V3, P16
[7]   Pentraxins as a key component of innate immunity [J].
Bottazzi, B ;
Garlanda, C ;
Salvatori, G ;
Jeannin, P ;
Manfredi, A ;
Mantovani, A .
CURRENT OPINION IN IMMUNOLOGY, 2006, 18 (01) :10-15
[8]   The systemic reaction during inflammation: The acute-phase proteins [J].
Ceciliani, F ;
Giordano, A ;
Spagnolo, V .
PROTEIN AND PEPTIDE LETTERS, 2002, 9 (03) :211-223
[9]   Production of modified C-reactive protein in U937-derived macrophages [J].
Ciubotaru, I ;
Potempa, LA ;
Wander, RC .
EXPERIMENTAL BIOLOGY AND MEDICINE, 2005, 230 (10) :762-770
[10]  
Dong Q, 1996, J IMMUNOL, V156, P4815